|
Dose | Model | Administration | Activity | Ref. |
|
25 μM | MCF-7 and MDA-MB-231 | Direct treatment | Apoptosis induction and anticancer effect | [129] |
20 μM | Human umbilical vein endothelial cells (HUVECs) | Direct treatment | Autophagy and promoted cell survival | [130] |
5.7 μM (DPPH assay) | Erythrocytes | Direct treatment | ROS and free radical scavenging activity | [131] |
100 mg kg-1 | C57BL/6J mice on ethanol-containing Lieber De Carli liquid diets | Gavage | Suppressed autophagic flux, decreased liver injury by ethanol consumption | [132] |
100 mg kg-1 | Streptococcus suis infected mice | Subcutaneous | Antimicrobial effect against Streptococcus suis | [133] |
100 mg kg-1 | Chronic ethanol feeding C57BL/6J mice | Oral | Decreased fat accumulation in liver (ethanol induced) | [134] |
30 mg kg-1 | STZ-induced diabetic rats | Intraperitoneal | Higher insulin levels, improved dyslipidemia, reduced serum blood glucose levels, decreased oxidative stress | [135] |
100-200 mg kg-1 | STZ-induced diabetic Wistar rats | Oral | Controlled insulin resistance, reduced blood sugar, pancreatic cells protection | [136] |
5-20 mg kg-1 | STZ-induced diabetic rats | Oral | Controlled body weight and blood glucose, performance in the Morris water test | [137] |
40 mg kg-1 | STZ-induced diabetic mice in the Morris water maze task | Oral | Enhanced the time spent by mice in the target quadrant in the Morris water maze task | [138] |
|